Highest-materiality recent filing
Oxbridge Re posts Q2 net income of $176K; launches AI GridWorks for data center development
Q2 2026 net income of $176K ($0.02/share) vs net loss of $1.87M ($0.25/share) in Q2 2025; no underwriting losses recorded.
Oxbridge Re enters new ATM sales agreement with Chardan for up to $1.68M in ordinary shares
New ATM agreement with Chardan Capital Markets replaces prior Maxim Group LLC agreement terminated June 20, 2026.
Oxbridge Re shareholders elect all five director nominees and ratify auditor at 2026 annual meeting
All five director nominees elected: Sanjay Madhu (2,593,023 for), Arun Gowda, Dwight Merren, Wrendon Timothy, Lesley Thompson.
Oxbridge Re Q1 net income $22k; tokenized reinsurance tokens target 25% and 42% returns
Net income of $22k (vs loss of $139k YoY); net premiums earned $555k, down from $595k.
Oxbridge Re Q4 net income $120K, full-year loss narrows; token returns beat targets
Q4 2025 net income $120K ($0.02/share) vs net loss $460K ($0.05 loss/share) year ago.
Oxbridge Re borrows $1M at 16% rate, secures with all assets via 6-month note
$1M principal borrowed from Real World Digital Assets LLC; 6-month maturity through Aug 14, 2026.
Oxbridge Re subsidiary launches $20M tokenized participation share offering
SurancePlus Inc. offering up to 2,000,000 Participation Shares at $10 each via digital tokens T20-2027 and T42-2027.
Oxbridge Re Q3 net loss narrows to $187K; expenses surge; token yields exceed targets
Net loss per share ($0.02) improved from ($0.09) YoY; net premiums earned $555K vs $595K.
Oxbridge Re files prospectus supplement for up to $2.02M in share sales under ATM program
Filed prospectus supplement to S-3 (333-287186) for sale of up to $2,021,889 of ordinary shares.
Authorized shares increased from 50M to 500M (450M new shares) via amendment to Memorandum and Articles, effective immediately.
Oxbridge Re Q2 net loss $1.87M; loss ratio 394% from Hurricane Milton
Net loss for Q2 2025: $1.87M ($0.25 per share) vs $821K ($0.14) in Q2 2024; six-month loss $2.01M ($0.28).
Oxbridge Re enters ATM equity offering agreement for up to $5M with Maxim Group
Equity Distribution Agreement with Maxim Group to sell up to $5M ordinary shares at-the-market.
Oxbridge Re shareholders approve issuance of >19.99% of shares on Series B warrants
Five director nominees elected: Madhu, Gowda, Merren, Timothy, Thompson; each with >2.5M votes for.
Net loss of $139K ($0.02 per share) vs $905K loss ($0.15) in Q1 2024.
Oxbridge Re reports FY 2024 net loss of $2.7M, improved from $9.9M; premiums up 83%
Net loss $2.7M ($0.45/share) vs $9.9M ($1.69) prior year; Q4 net loss $460K vs $2.67M prior year.
Up to 1M Participation Shares at $10 each; discounts of 5%/10% for investments >$50K/$100K.
Oxbridge Re raises $3.0M via registered direct offering and warrants issuance
Sold 705,884 ordinary shares, 529,413 Series A warrants, and 882,355 Series B warrants at $4.25 combined effective price.
SurancePlus Holdings Ltd. offers up to $5 million of its ordinary shares to accredited investors under Rule 506(c) and Regulation S.
Oxbridge Re discloses max $1.7M potential hurricane loss; no claims yet
No claims received from ceding insurers related to Hurricanes Helene and Milton.
Oxbridge Re Q3 net loss narrows to $540K from $7.3M; new token offerings planned
Net loss of $540K ($0.09/share) vs $7.3M ($1.24) in Q3 2023; nine-month loss $2.27M vs $7.2M.
Oxbridge Re Q2 net loss $821K; completes $2.88M tokenized reinsurance placement
Net loss $821K ($0.14 per share) for Q2 2024 vs net loss $85K ($0.01) in Q2 2023; year-to-date net loss $1.73M vs net profit $57K prior year.
287,705 Participation Shares sold at $10.00 each for gross proceeds of $2,878,048.
Oxbridge Re Holdings holds 2024 AGM; elects directors and ratifies auditor
Five director nominees elected: Sanjay Madhu, Arun Gowda, Dwight Merren, Wrendon Timothy, Lesley Thompson.
Oxbridge Re evaluates strategic alternatives including sale or merger
Board formed Special Committee to explore strategic alternatives for Co. and/or Web-3 unit SurancePlus Holdings.
Oxbridge Re Q1 net loss $905K vs net income $142K; premiums earned $549K
Net loss of $905K (($0.15) per share) vs net income $142K ($0.02) in Q1 2023.
Oxbridge Re subsidiary SurancePlus launches $3M private placement; 500K parent warrants offered
SP Holdings offering up to $3,000,000 of its ordinary shares in private placement.
Oxbridge Re subsidiary adopts 2024 equity plan; grants restricted shares and options to executives
SPH 2024 Equity Incentive Plan adopted, reserving 750,000 SPH ordinary shares for awards.
Oxbridge Re FY2023 net loss widens to $9.9M; tokenized reinsurance returns >45%
Net loss of $9.9M ($1.69/share) for FY2023 vs $1.8M ($0.31/share) loss in prior year.
SurancePlus, Oxbridge Re subsidiary, commenced offering of up to 1,000,000 Participation Shares at $10 per share, represented by digital tokens 'EpsilonCat Re'.
Oxbridge Re extends warrant expiration to March 2029; exercise price $7.50
Warrants exercisable for 8,230,700 ordinary shares at $7.50 per share, originally expiring March 26, 2024.
Oxbridge Re posts investor presentation for Sequire Summit; no new financial data disclosed
CEO Jay Madhu to present at Sequire Investor Summit on Jan 24, 2024 in San Juan, Puerto Rico.
Oxbridge Re Q3 net loss $7.3M vs $2.2M YoY; SurancePlus generates $300K in fees
Net loss of $7.3M ($1.24 diluted EPS) in Q3 2023 vs $2.2M ($0.37) YoY; nine-month loss $7.2M ($1.23) vs $2.5M.
Oxbridge Re Q2 net loss $85k; SurancePlus token offering raises $2.45M; SPAC merger closed
Q2 2023 net loss of $85,000 ($0.01 per share) vs net income of $77,000 ($0.01 per share) in Q2 2022.
SurancePlus raised $2,447,760 through sale of 244,776 DeltaCat Re tokens at $10.00 each.
Oxbridge Re posts investor presentation for LD Micro Conference; no new financial metrics disclosed
Presentation furnished for 13th Annual LD Micro Invitational Conference, June 6-8, 2023, at Luxe Sunset Boulevard Hotel.
Oxbridge Re shareholders elect five directors, ratify auditor at 2023 annual meeting
Sanjay Madhu re-elected with 2.17M votes for; 44,986 against; 2.35M broker non-votes.
Oxbridge Re posts Q1 net income of $142k; launches SurancePlus token offering
Q1 2023 net income $142k ($0.02 per share) vs net loss $387k ($0.07 loss) in Q1 2022.
Q4 net income $678k ($0.12 EPS) vs $1.6M ($0.27) prior year; full year net loss $1.8M ($0.31) vs income $8.6M ($1.49).
SurancePlus offering up to $5.0M of DeltaCat Re Tokens at $10/token, each representing a Preferred Share.
Oxbridge Re appoints new independent director, adopts director comp, amends CEO/CFO contracts
Director Raymond Cabillot resigned Jan 9, 2023; no disagreement with company.
Oxbridge Re appoints Dwight Merren as independent director after Kris Persaud resigns
Kris Persaud resigned as independent director effective Nov 11, 2022, with no disagreement with company.
Oxbridge Re Q3 net loss $2.2M vs income $6.5M; Hurricane Ian drives underwriting loss
Net loss of $2.2M ($0.37/share) in Q3 2022, compared to net income of $6.5M ($1.14/share) in Q3 2021.
Oxbridge Re enters ATM equity facility for up to $6.3M; estimates Hurricane Ian loss up to $500k
Enters Equity Distribution Agreement with Maxim Group LLC to sell up to $6.3M of ordinary shares at-the-market, with a 3% commission.
Oxbridge Re reports Q2 net income $77k, H1 net loss $310k; combined ratio rises
Q2 net income $77k ($0.01/share) vs $448k ($0.08) in Q2 2021.
Oxbridge Re shareholders elect directors and ratify auditor at 2022 annual meeting
All five director nominees elected: Madhu (2,041,081 for), Persaud (2,026,126), Cabillot (1,851,848), Timothy (2,026,229), Thompson (2,025,294).
Oxbridge Re posts Q1 net loss of $387K on unrealized investment losses; premiums rise
Net loss of $387K ($0.07 per share) vs $28K loss in Q1 2021, driven by negative unrealized change in investments.
Each of Raymond Cabillot and Kris Persaud received 16,000 restricted ordinary shares under 2014 Omnibus Incentive Plan.
Oxbridge Re swings to FY2021 profit of $8.6M on $9.2M SPAC unrealized gain
FY2021 net income $8.6M ($1.49 diluted EPS) vs net loss $50K (-$0.01) in FY2020.
Oxbridge Re resolves audit committee non-compliance; Nasdaq closes matter
Received Nasdaq letter Dec 8, 2021 noting non-compliance from June 30 to Nov 12, 2021.
Oxbridge Re appoints two directors, grants 16,000 restricted shares to new independent director
Lesley Thompson appointed independent director, filling vacancy from June 2021; also appointed to Compensation, Nominating & Governance, and Underwriting Committees.
accepted the resignation of Mr. Raymond Cabillot as an independent director of the Company, effective immediately.
appointed Mr. Arun Gowda to serve as an independent director on the Board of the Company, effective immediately.
On November 11, 2022, the Board of Oxbridge Re Holdings Limited appointed Mr. Dwight Merren, to serve as an independent director on the Board of the Company, effective immediately, and Oxbridge Reinsurance Limited (“OxRe”), subject to approval of the Cayman Islands Monetary Authority (“CIMA”).
On November 11, 2022, the Board of Directors (the “Board”) of Oxbridge Re Holdings Limited (the “Company”) accepted the resignation of Mr. Kris Persaud as an independent director of the Company, effective immediately.
On November 12, 2021, the Board also expanded the size of the Board to five members and appointed Wrendon Timothy, effective immediately, to serve as a director on the boards of Oxbridge Re Holdings Limited and Oxbridge Reinsurance Limited.
On November 12, 2021, the Board of Directors (the “Board”) of Oxbridge Re Holdings Limited (the “Company”) appointed Ms. Lesley Thompson, effective immediately, to serve as a director on the boards of the Company and Oxbridge Reinsurance Limited (“OxRe”).
On June 30, 2021, Dr. Mayur Patel, a director of Oxbridge Re Holdings Limited (the “Company”), notified the Company that he has decided to resign from the Company’s Board of Directors effective June 30, 2021.
Max materiality 0.75 · Median 0.55 · Most common event other_material